Moritz Fürstenau - Concepedia

Author

Moritz Fürstenau

University Hospital Cologne ORCID

Also Known As

Fürstenau, Moritz Alexander, M Fürstenau, M. Fürstenau, Moritz Fürstenau, Moritz Furstenau, Moritz Fürstenau

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

University Hospital Cologne Düsseldorf University Hospital Heinrich Heine University Düsseldorf University of Cologne Rigshospitalet

About

Moritz Fürstenau is an author at University Hospital Cologne specializing in medicine, clinical trials, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	88
2	Health Sciences	2	2	43
3	Immunology	2	2	59
4	Pathology	2	2	43
5	Pharmacology	1	1	29

Moritz Fürstenau

Publications

931

Citations

H-Index

Page 1

	Year	Citations
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater, New England Journal of Medicine	2023	268
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study Thomas Chatzikonstantinou, Anargyros Kapetanakis, Lydia Scarfò, Leukemia	2021	94
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia Petra Langerbeins, Can Zhang, Sandra Robrecht, Blood	2021	87
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial Moritz Fürstenau, Arnon P. Kater, Sandra Robrecht, The Lancet Oncology	2024	59
Efficacy of Mefloquine Intermittent Preventive Treatment in Pregnancy Against Schistosoma haematobium Infection in Gabon: A Nested Randomized Controlled Assessor-Blinded Clinical Trial Arti Basra, Ghyslain Mombo‐Ngoma, Meskuere Capan Melser, Clinical Infectious Diseases	2012	57
COVID-19 among fit patients with CLL treated with venetoclax-based combinations Moritz Fürstenau, Petra Langerbeins, Nisha De Silva, Leukemia Clinical Infectious DiseaseCovid-19 PandemicImmunologyAntiviral TherapyChronic Viral Infection	2020	45
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia H. Huber, Simone Edenhofer, Julia von Tresckow, Blood	2022	44
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/<i>TP53</i>mut H. Huber, Eugen Tausch, Christof Schneider, Blood	2023	42
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Blood	2023	35
A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater, Blood	2021	33

Page 1